title: [Pharmacoeconomic aspects of use of structum in osteoarthrosis].
abstract: OBJECTIVE
  To study cost-effect efficiency of structum in patients with knee and hip joint osteoarthrosis (OA) in a multicenter trial.
  
  
  METHODS
  The trial enrolled 192 patients with OA. 110 patients had knee joint OA and 82 patients hip joint OA. The patients received structum for 6 months. Efficacy of the treatment was assessed before use of structum and after it by standard methods. Integral effect of therapy was estimated according to the special program complex. The cost of the drug therapy included the cost of structum and nonsteroid anti-inflammatory drugs (NSAID) on conversion to 1 mg of diclofenac plus the cost of treating side effects. The efficacy per unit cost was calculated by the formula: E1xC2/E2xC1, where E1--integral efficacy of therapy before using structum, E2--integral efficacy of therapy in administration of structum, C1--cost of drug therapy, C2--cost of drug therapy in using structum.
  
  
  RESULTS
  E2 was equal to 94% for knee joints OA and 92% for hip joint OA, E1 and C1--21 and 19%, respectively. C2 was equal to 108.43$ for knee joint OA and 106.97 for hip joint OA, C1--29.3 and 27.44, respectively. The efficacy per unit cost for knee joint OA was 94 x 29.3/21 x 108.3 = 1.21, for hip joint OA 92 x 27.44/19 x 106.97 = 1.24. The figures evidence for much higher efficacy per unit cost of structum vs routine NSAID.
  
  
  CONCLUSIONS
  The multicenter trial gave grounds not only for clinical efficacy of structum vs NSAID but also for cost-effect advantage of structum in therapy of OA.
authors.forename: L I
authors.initials: LI
authors.lastname: Alekseeva
authors.forename: B L
authors.initials: BL
authors.lastname: Mednikov
authors.forename: S A
authors.initials: SA
authors.lastname: Piiavskiĭ
authors.forename: V A
authors.initials: VA
authors.lastname: Nasonova
authors.forename: D G
authors.initials: DG
authors.lastname: Soldatov
mesh_terms: D002809:Chondroitin Sulfates / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D005260:Female; D006621:Hip Joint; D006801:Humans; D007719:Knee Joint; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy / Q000191:economics*
chemical_list: D002809:Chondroitin Sulfates